Takeda launches CINRYZE™ in India, the first C1-I NH for prophylaxis in hereditary angioedema patients
Clinical Policy Bulletin: Hereditary Angioedema
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
Cinryze: Package Insert - Drugs.com
Takeda launches CINRYZE™ in India, the first C1-I NH for prophylaxis in hereditary angioedema patients